Drug intelligence / Profile preview

HN43001

Development stage: Preclinical
Lead developer: Hana Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

HN43001 is an incrementally modified drug (IMD) currently in the discovery phase of development by Hana Pharm. It is being investigated for the treatment of peptic ulcers. As an IMD, the candidate is likely a modified version of an existing therapeutic agent, designed to offer improvements in safety, efficacy, or administration. Specific details regarding its chemical structure or molecular target have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on HN43001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HN43001.

Explore the full profile